Pathology and aspects of pathogenesis in Pulmonary Arterial Hypertension

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 20, Issue 1, 2003, Pages 9-19

  Dorfmüller, Peter ^a,b,c   Humbert, Marc ^a   Capron, Frédérique ^a   Müller, Klaus Michael ^b  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c INSTITUT FÜR PATHOLOGIE   (Germany)

Author keywords

Chemokines; Endothelial cell; Inflammation; Plexiform lesion; Primary Pulmonary Hypertension; Pulmonary Arterial Hypertension

Indexed keywords

ARTERY DISEASE; CELL PROLIFERATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; HYPERTROPHY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; THROMBOCYTE DISORDER; TUNICA MEDIA; WORLD HEALTH ORGANIZATION;

FIBROSIS; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; MUSCLE, SMOOTH, VASCULAR; PULMONARY ARTERY;

EID: 0037878058     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Müller KM, Müller AM: Pulmonale Hypertonie - Pathologische Anatomie. Atemw.-Lun. genkrkh 2000; 7: 346-53.
2. Rubin LJ: Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-7.
3. Pietra GG: The pathology of primary pulmonary hypertension. In: L. Rubin, and S. Rich, editors: Primary pulmonary hypertension. Marcel Dekker, New York 1997; 19-61.
4. Romberg E: Uber die Sklerose der Lungenarterien. Dtsch Arch Klin Med. 1891; 48: 197.
5. Dresdale DT, Schultz M, Mitchom RJ. Primary pulmonary hypertension: clinical and hemodynamic study. Am J Med 1951; 11: 686-94.
6. Heath D, Edwards JE: The pathology of hypertensive pulmonary vascular disease. Circulation 1958; 18: 533-47.
7. Waagenvoort CA, Waagenvoort N: Primary pulmonary hypertension: a pathological study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970; 42: 1163-84.
8. Hatano S, Strasser T, eds: Primary pulmonary hypertension. Report on a WHO-meeting October 15-17. Geneva, WHO 1975.
9. Rich S, Dantzer DR, Ayres SM, et al: Primary pulmonary hypertension: a national prospective study Ann Intern Med 1987; 107: 216-23.
10. Primary Pulmonary Hypertension: Executive Summary from the World Symposium - Primary Pulmonary Hypertension, Evian. France, 1998. Available from the World Health Organization via the internet (http://www.who.int/ncd/cvd/pph.html).
11. Bjornsson J, Edwards WD: Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 1985; 60: 16-25.
12. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL: Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-7.
13. Rich S: Primary pulmonary hypertension. Prog Cardiovas Dis 1988; 31: 205-38.
14. Dorfmüller P, Zarka V, Durand-Gasselin I, et al: Chemokine RANTES in severe pulmonary arterial hypertension. Am J Resp Crit Care Med 2002; 165: 534-9.
15. 3C chemokine fractalkine in pulmonary arterial hypertension. Am J Resp Crit Care Med 2002; 165: 1419-25.
16. Humbert M, Monti G, Brenot F, et al: Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 1628-31.
17. Tron V, Magee F, Wright L, Colby F, Churg A: Pulmonary capillary hemangiomatosis. Hum Pathol 1986; 17: 1144-50.
18. Faber CN, Yousem SA, Dauber JH, Griffith BP, Hardesty RL, Paradis IL: Pulmonary capillary hemangiomatosis: a report of three cases and a review of the literature. Am Rev Respir Dis 1989; 140: 808-13.
19. Schraufnagel DE, Sekosan M, McGee T, Thakkar MB: Human alveolar capillaries undergo angiogenesis in pulmonary venoocclusive disease. Eur Respir J 1996; 9: 346-50.
20. Humbert M, Maitre S. Capron F, Rain B, Musset D, Simonneau G: Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998; 157: 1681-5.
21. Dufour B, Maitre S, Humbert M, Capron F, Simonneau G, Musset D: High resolution computed tomography of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. Am J Roentgenol 1998; 171: 1321-4.
22. Palmer SM, Robinson LJ, Wang A, Gossage JR, Bashore T, Tapson VF: Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998; 113: 237-240.
23. Hervé P, Launay JM, Scrobohaci ML, et al: Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-54.
24. Loscalzo J: Endothelial dysfunction in pulmonary hypertension. N Engl J Med 1992; 327: 117-9.
25. Giaid A, Yanagisawa M, Langleben D, et al: Expression of endothelin 1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-9.
26. Giaid A, Saleh D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-21.
27. Christman BW, McPherson CD, Newman JH, et al: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-5.
28. Tuder RM, Cool CD, Geraci MW, et al: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-32.
29. Olschewski H, Seeger W: Pulmonary hypertension, Pathophysiology, diagnosis, treatment, and development of a pulmonary-selective therapy (UNI-MED, Bremen, 2002).
30. Lopes AA, Maeda NY: Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension. Chest 1998; 114: 1276-82.
31. Lopes AA, Maeda NY, Goncalves RC, Bydlowski SP: Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. Am Heart J 2000; 139: 618-23.
32. Welsh CH, Hassell KL, Badesch DB, et al: Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110: 710-7.
33. Lee SD, Shroyer KR, Markham NE, Coll CD, Voelkel NF, Tuder RM: Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998; 101: 927-34.
34. Nichols WC, Koller DL, Slovis B, et al: Localization of the gene for familial primary hypertension to chromosome 2q31-32. Nature Genetics 1997; 15: 277-80.
35. Machado RD, Pauciulo MW, Thomson JR, et al: BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68: 92-102.
36. Trembath RC, Thomson JR, Machado RD, et al: Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia: N Engl J Med 2001; 345: 325-34.
37. Deng Z, Morse JH, Slager SL, et al: Familial primary pulmonary hypertension gene PPH1 is caused by mutations in bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-44.
38. Thomson JR, Machado RD, Panciulo MW, et al: Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding for BMPR-II, a receptor of the TGF-beta family. J Med Gen 2000; 37: 741-5.
39. Voelkel NF, Tuder RM, Bridges J, Arend WP: Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 1994; 11: 664-75.
40. Kimura H, Kasahara Y, Kurosu K, et al: Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 1998; 78: 571-81.
41. Humbert M, Monti G, Fartoukh M, et al: Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11: 554-9.
42. Tuder RM, Groves B, Badesch DB, Voelkel NF: Exuberant endothelial cell growth and element of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-85.
43. Cool CD, Kennedy D, Voelkel NF, Tuder RF: Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection Hum Pathol 1997; 28: 434-42.
44. Sanchez O, Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999; 54: 273-7.
45. Humbert M, Nunes H, Sitbon O, Parent P, Hervé P, Simonneau G: Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001; 22: 459-75.
46. Lesprit P, Godeau B, Authier FJ, et al. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med 1998; 157: 907-11.
47. Opravil M, Pechere M, Speich R, et al: HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Resp Crit Care Med 1997; 155: 990-5.
48. Kopelman RG, Zolla Pazner S: Association of human immunodeficiency virus infection and autoimmune phenomena. Am J Med 1988; 84: 82-8.
49. Isern RA, Yaneva M, Weiner E, et al: Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku. Am J Med 1992; 93: 307-12.
50. Fartoukh M, Emilie D, Le Gall C, Monti G, Simonneau G, Humbert M: Chemokine MIP-1α expression in lung biopsies of primary pulmonary hypertension. Chest 1998; 114: S50-51.
51. Springer TA: Traffic signals for lymphocyte recirculation and leucocyte emigration: the multistep paradigm. Cell 1994; 76: 301-14.
52. Zlotnik A, Yoshie O: Chemokines: A new classification system and their role in immunity. Immunity 2000; 12: 121-7.
53. 3C motif. Nature 1997; 385: 840-4.
54. Papadopoulos EJ, Sassetti C, Saeki H, et al: Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. Eur J Immunol 1999; 29: 2551-9.
55. Foussat A, Coulomb-Lhermine A, Gosling J, et al: Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol 2000; 30: 87-97.
56. Harrison JK, Jiang Y, Chen S, et al: Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA 1998; 95: 10896-910.
57. 3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91: 521-30.
58. Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM: Identification of CX3CR1. J Biol Chem 1998; 273: 23799-804.
59. Papadopoulos EJ, Fitzhugh DJ, Tkaczyk C, et al: Mast cells migrate, but do not degranulate, in response to fractalkine, a membrane-bound chemokine expressed constitutively in diverse cells of the skin. Eur J Immunol 2000; 30: 2355-61.
60. Fraticelli P, Sironi M, Bianchi G, et al: Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001; 107: 1173-81.
61. Haskell CA, Cleary MD, Charo IF: Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. J Biol Chem 1999; 274: 10053-8.
62. 3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998; 188: 1413-9.
63. 3CR1. Kidney Int 1999; 56: 612-20.
64. Moatti D, Faure S, Fumeron F, et al: Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary, artery disease. Blood 2001; 97: 1925-8.
65. McDermott DH, Halcox JP, Schenke WH, et al: Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 2001; 89: 401-7.
66. Luster AD: Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-45.
67. Schall T, Bacon K, Toy K, Goeddel D: Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1998; 347: 669-71.
68. Cockwell P, Howie AJ, Adu D, Savage CO: In situ analysis of C-C chemokine mRNA in human glomerulonephritis. Kidney Int 1998; 54: 827-36.
69. Wong M, Silverman ED, Fish EN: Evidence for RANTES, monocyte chemotactic protein-1, and macrophage inflammatory protein-I beta expression in Kawasaki disease. J Rheumatol 1997; 24: 1179-85.
70. Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G: Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999; 100: 55-60.
71. Chen S, Bacon KB, Li L, et al: In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIPII. J Exp Med 1998; 188: 193-8.
72. Liang M, Mallari C, Rosser M, et al: Identification and characterization of a potent, selective and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 2000; 275: 19000-8.
73. Grone HJ, Weber C, Weber KS, et al: IMet-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB 1999; 13: 1371-83.
74. Molet S, Furukawa K, Maghazechi A, Hamid Q, Giaid A: Chemokine- and cytokine-induced expression of endothelin I and endothelin-converting enzyme I in endothelial cells. J Allergy Clin Immunol 2000; 105: 333-8.